Clinical Trial Update: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). [Phase 1]

View source ↗

Summary

Phase 1 trial of BI 655064 for chronic primary immune thrombocytopenic purpura (ITP) in adults was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura
• Immune Thrombocytopenic Purpura

Drugs mentioned

• BI 655064

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Purpura, Thrombocytopenic, Idiopathic | Phase 1 | Status: TERMINATED | Results posted: 2024-03-15